Pfizer announces hestitance to launch Amsparity in EU

by , | Feb 28, 2020

Despite receiving CHMP approval earlier this month, Pfizer has announced it does not currently plan to launch Amsparity (adalimumab) in the EU, citing unfavourable market conditions.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to recieve our updates via email.

Our Latest News